Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2006 pp 619–628Cite as

Durchblutungsfördernde Mittel

  • Chapter

  • 416 Accesses

Auszug

Die Verordnungen durchblutungsfördernder Arzneimittel haben seit 1992 um 76% abgenommen. Auch 2005 ist das Verordnungsvolumen erneut um 8% zurückgegangen. Hauptursache ist die fragliche Wirksamkeit der Vasodilatatoren, die eine Anwendung nach den aktuellen Therapieempfehlungen nicht mehr rechtfertigen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86.

    Article  Google Scholar 

  • Arnold A (2004): Der plötzliche Hörsturz. Therap Umschau 61: 30–34.

    Article  CAS  Google Scholar 

  • Arzneimittelkommission der Deutschen Apotheker (1995): Naftidrofuryl Infusionslösung. Pharmazeut Ztg 140: 2222.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der peripheren arteriellen Verschlusskrankheit (pAVK). 3. Auflage. Arzneiverordnung in der Praxis, Band 31 Sonderheft 3. Im Internet unter: www. akdae.de/35/72_pAVK_2004_3Auflage.pdf

    Google Scholar 

  • Barradell LB, Brogden RN (1996): Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299–322.

    PubMed  CAS  Google Scholar 

  • Boccalon H, Lehert P, Mosnier M (2001): Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angéiol 50: 175–182.

    Article  CAS  Google Scholar 

  • Böhme H, Brülsaver M, Härtel U, Bollinger A (1987): Kontrollierte Studie zur Wirksamkeit von I. A. PGE, Infusionen bei peripherer arterieller Verschlußkrankheit im Stadium III und IV. Vasa 20(Suppl): 206–208.

    Google Scholar 

  • Burns P, Gough S, Bradbury AW (2003): Management of peripheral arterial disease in primary care. Brit Med J 326: 584–588.

    Article  PubMed  Google Scholar 

  • De Backer TL, Van der Stichele RH, Warie HH, Bogaert MG (2000): Oral vasoactive medication in intermittent claudication: utile or futile?. Eur J Clin Pharmacol 56: 199–206.

    Article  PubMed  Google Scholar 

  • Diehm C, Hübschmüller C, Stamller F (1988): Intravenöse Prostaglandin E1-Therapie bei Patienten mit peripherer arterieller Verschlußkrankheit (AVK) im Stadium III: Eine doppelblinde, Placebo-kontrollierte Studie. In: Heinrich H, Böhme H, Rogatti W (Hrsg): Prostaglandin E1-Wirkungen und therapeutische Wirksamkeit. Springer-Verlag, Heidelberg, S. 133–143.

    Google Scholar 

  • Dormandy JA, Rutherford RB (2000): Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter-Society Consensus (TASC). J Vasc Surg 31: S1–S296.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E (1994): Pentoxifylline for intermittent claudication. A critical review. Angiology 45: 339–345.

    Article  PubMed  CAS  Google Scholar 

  • Girolami B, Bernardi E, Prins MH, Wouter ten Cate J, Hettiarachchi R et al. (1999): Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. Arch Intern Med 159: 337–345.

    Article  PubMed  CAS  Google Scholar 

  • Hiatt WR (2001): Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344: 1608–1621.

    Article  PubMed  CAS  Google Scholar 

  • Hiatt WR (2002): Pharmacological therapy for peripheral arterial disease and claudication. J Vasc Surg 36: 1283–1291.

    Article  PubMed  Google Scholar 

  • Hirsch AT, Haskal ZJ, Hertzer NR, et al. (2006): ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). J Am Coll Cardiol 47: 1239–312.

    Article  PubMed  Google Scholar 

  • Housley E (1988): Treating claudication in five words. Brit Med J 296: 1483–1484.

    Article  CAS  Google Scholar 

  • Leng GC, Fowler B, Ernst E (2000): Exercise for intermittent claudication. Cochrane Database Syst Rev (2): CD000990.

    Google Scholar 

  • McDermott MM, Liu K, Ferrucci L, Criqui MH, Greenland P, Guralnik JM, Tian L, Schneider JR, Pearce WH, Tan J, Martin GJ (2006): Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 144: 10–20.

    PubMed  Google Scholar 

  • Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ et al. (1998): Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81: 333–335.

    Article  PubMed  CAS  Google Scholar 

  • Probst R, Tschopp K, Ludin E, Kellerhals B, Podvinec M, Pfaltz CR (1992): A randomized, double-blind, placebo-controlled study of dextran/pentoxifylline medication in acute acoustic trauma and sudden hearing loss. Acta Otolaryngol 112: 435–443.

    PubMed  CAS  Google Scholar 

  • Radack K, Wyderski RJ (1990): Conservative management of intermittent claudication. Ann Intern Med 113: 135–146.

    PubMed  CAS  Google Scholar 

  • Reisser C, Weidauer H (2001): Ginkgo biloba extract Egb 761® or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, doubleblind study. Acta Otolaryngol 121: 579–584.

    Article  PubMed  CAS  Google Scholar 

  • Reiter M, Bucek RA, Stumpflen A, Dirisamer A, Minar E (2002): Prostanoids in the treatment of intermittent claudication — a metaanalysis. VASA 31: 219–224.

    Article  PubMed  CAS  Google Scholar 

  • Reiter M, Bucek RA, Stumpflen A, Minar E (2004): Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2004 (1): CD000986.

    Google Scholar 

  • Sakaguchi S (1984): Prostaglandin E1 intra-arterial infusion therapy in patients with ischemic ulcer of the extremities. Int Angiol 3: 39–42.

    Google Scholar 

  • Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E (2006): Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354: 1879–1888.

    Article  PubMed  CAS  Google Scholar 

  • The Ciprostene Study Group (1991): The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. J Clin Pharmacol 31: 81–87.

    Google Scholar 

  • The ICAI Study Group (1999): Prostanoids for chronic critical leg ischaemia: a randomized, controlled, open-label trial with prostaglandin E1. Ann Intern Med 130: 412–421.

    Google Scholar 

  • Transparenzkommission (1983): Transparenzliste für das Teilgebiet periphere arterielle Durchblutungsstörungen. Bundesanzeiger Nr. 169 vom 9.9.1983.

    Google Scholar 

  • Trübestein G, Diehm C, Gruss JD, Horsch S (1987): Prostaglandin E1 in chronic arterial disease: a multicentre study. Vasa 17(Suppl): 39–43.

    Google Scholar 

  • Trübestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H et al. (1989): Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease: a controlled randomised multicenter study. Vasa 28(Suppl): 44–49.

    Google Scholar 

  • Walker GA, MacMannaford JC (1995): A meta-analysis of randomized, doubleblind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundam Clin Pharmacol 9: 387–394.

    Article  PubMed  CAS  Google Scholar 

  • Weinaug P (1984): Die Spontanremission beim Hörsturz. HNO 32: 346–351.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2007). Durchblutungsfördernde Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34370-7_26

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34369-1

  • Online ISBN: 978-3-540-34370-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation